Twist Bioscience (NASDAQ:TWST) PT Raised to $60.00

Twist Bioscience (NASDAQ:TWST) had its price objective boosted by equities research analysts at Barclays from $45.00 to $60.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Barclays‘s price objective points to a potential upside of 21.75% from the company’s current price.

A number of other brokerages have also recently issued reports on TWST. TD Cowen increased their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a research note on Thursday, June 13th. Scotiabank increased their price target on shares of Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a research report on Monday, May 6th. Evercore ISI increased their price target on shares of Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. Guggenheim initiated coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They set a “buy” rating and a $53.00 target price on the stock. Finally, Robert W. Baird raised their target price on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a report on Friday, May 3rd. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $48.50.

Twist Bioscience Trading Up 3.8 %

Twist Bioscience stock opened at $49.28 on Friday. The company’s 50-day moving average price is $43.84 and its two-hundred day moving average price is $38.34. The stock has a market cap of $2.87 billion, a price-to-earnings ratio of -14.67 and a beta of 1.78. Twist Bioscience has a 52 week low of $14.42 and a 52 week high of $55.26.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.05. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The company had revenue of $75.30 million during the quarter, compared to analyst estimates of $70.70 million. During the same quarter last year, the business posted ($1.06) EPS. The company’s revenue for the quarter was up 25.1% on a year-over-year basis. Research analysts expect that Twist Bioscience will post -3.08 earnings per share for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,132 shares of the business’s stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $32.74, for a total value of $37,061.68. Following the transaction, the chief executive officer now directly owns 514,149 shares of the company’s stock, valued at $16,833,238.26. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, COO Patrick John Finn sold 2,174 shares of the company’s stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $30.12, for a total transaction of $65,480.88. Following the transaction, the chief operating officer now directly owns 176,206 shares of the company’s stock, valued at $5,307,324.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Emily M. Leproust sold 1,132 shares of the stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $32.74, for a total value of $37,061.68. Following the completion of the sale, the chief executive officer now directly owns 514,149 shares of the company’s stock, valued at $16,833,238.26. The disclosure for this sale can be found here. Over the last three months, insiders have sold 19,426 shares of company stock valued at $777,966. 3.92% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. UBS Group AG grew its position in shares of Twist Bioscience by 106.4% during the 4th quarter. UBS Group AG now owns 213,467 shares of the company’s stock valued at $7,868,000 after acquiring an additional 110,036 shares during the period. Nikko Asset Management Americas Inc. grew its position in shares of Twist Bioscience by 2.9% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company’s stock valued at $131,835,000 after acquiring an additional 99,511 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Twist Bioscience by 3.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 442,504 shares of the company’s stock valued at $8,965,000 after acquiring an additional 14,511 shares during the period. Artisan Partners Limited Partnership grew its position in shares of Twist Bioscience by 111.3% during the 4th quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock valued at $137,241,000 after acquiring an additional 1,961,621 shares during the period. Finally, Trexquant Investment LP grew its position in shares of Twist Bioscience by 104.6% during the 4th quarter. Trexquant Investment LP now owns 131,683 shares of the company’s stock valued at $4,854,000 after acquiring an additional 67,320 shares during the period.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.